Approval

Approval  ·  Weekly Digest 29 March to 04 April 2025
Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic Breast cancer following at least one endocrine therapy

Weekly Digest – April 2025 Weekly Digest – April 2025 04 Apr 2025: Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic Breast cancer following at least one endocrine therapy The European […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 29 March to 04 April 2025
TIVDAK (Tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic Cervical cancer

Weekly Digest – April 2025 Weekly Digest – April 2025 31 Mar 2025: TIVDAK (Tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic Cervical cancer The European Commission has approved TIVDAK (Tisotumab vedotin) as the first and […]

by Sandhya Ramalingam

Continue Reading